Bruce D. Cheson, MD
Treatment with copanlisib (Aliqopa) led to a median progression-free survival (PFS) of 11.2 months and objective response rate (ORR) of 59.2% in patients with relapsed/refractory indolent lymphoma, according to results from the phase II CHRONOS-1 trial recently published in the Journal of Clinical Oncology.
“The drug is given weekly for 3 weeks, then a week off, then it’s given indefinitely, which is a burden on patients, particularly those who travel a distance to see their doctor,” Cheson said. “It’ll be challenging to get patients to be as compliant as you would like them to be, but I’m sure easier maintenance schedules will be developed to mitigate this problem.”
Dreyling M,, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma [published online October 4, 2017]. doi:10.1200/JCO.2017.75.4648.
... to read the full story